Priligy and PSD502/TEMPE are expected to Drive Growth in the Premature Ejaculation Market: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com. It is expected to increase in value by around 10.3% p/a to 2017, reaching $1.3 billion, on account of the anticipated US and European approval of Priligy (dapoxetine).

Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.companiesandmarkets.com/Market-Report/premature-ejaculation-(pe)-therapeutics-pipeline-assessment-and-market-forecasts-to-2017-614353.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The premature ejaculation medication market represents a distinct unmet treatment need, as there are very few therapies in development, and those that are in use tend to be off-label (i.e., prescribed for an unapproved indication), such as SSRIs.

Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment (and not in all countries).

Off-label drugs administered for the treatment of premature ejaculation include Prozac (fluoxetine), Zoloft (sertraline) and Paxil (paroxetine).

At present, physicians’ preferred treatment for premature ejaculation is a behavioural method termed ‘stop and squeeze’, which yields satisfactory results and has no side effects.

It is estimated that the premature ejaculation market was valued at US$684 million in 2010, with the sector forecast to expand at 10.3% compound annual growth rate to 2017. By the end of 2017, the premature ejaculation market is forecast to be valued at US$1.3 billion. The expected approval of the branded drug Priligy (dapoxetine) and the prevalence of PE in the male population is expected to drive this growth.

The 67 page premature ejaculation market report, published in July 2011, includes historical and forecast data between 2005-2017. It provides the reader with an overview of the premature ejaculation therapeutic market, including profiles of key companies such as Shionogi & Co, Vectura Group plc, GlaxoSmithKline and Dong-A Pharmaceutical Co., Ltd.

Subjects examined in detail include competitor analysis, product pipelines, trials by region and by product type, mergers/acquisitions and licensing, amongst many others. Geographies analysed within the premature ejaculation treatment forecast research report include France, Germany, Italy, Spain, Japan, UK and US.

Report Details:

http://www.companiesandmarkets.com/Market-Report/premature-ejaculation-(pe)-therapeutics-pipeline-assessment-and-market-forecasts-to-2017-614353.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companiesandmarkets.com
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.